

WEST Search History

DATE: Friday, June 13, 2003

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ

L4	(bronchitis or bronchie\$7 or asthma or cystic fibrosis) same (kunitz or bikunin or aprotinin)	30	L4
L3	L2 and (serine protease or elastase)	451	L3
L2	(bronchitis or bronchie\$7 or asthma or cystic fibrosis) and (kunitz or bikunin or aprotinin)	1443	L2
L1	mucociliary clearance and (kunitz or bikunin or aprotinin)	12	L1

END OF SEARCH HISTORY

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 12 of 12 returned.☐ 1. Document ID: US 20030109482 A1

L1: Entry 1 of 12

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030109482

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030109482 A1

TITLE: Regulation of human p2y8-like g protein-coupled receptor

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ramakrishnan, Shyam	Brighton	MA	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 2. Document ID: US 20030007930 A1

L1: Entry 2 of 12

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030007930

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030007930 A1

TITLE: Novel methods and compositions for delivering macromolecules to or via the respiratory tract

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bot, Adrian I.	San Diego	CA	US	
Dellamary, Luis A.	San Marcos	CA	US	
Smith, Dan J.	San Diego	CA	US	

US-CL-CURRENT: 424/45

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 3. Document ID: US 20020086020 A1

L1: Entry 3 of 12

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086020

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086020 A1

TITLE: Method for improving the half-life of soluble viral receptors on mucosal membranes

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lee, Peter P.	Menlo Park	CA	US	

US-CL-CURRENT: 424/147.1; 424/133.1, 424/134.1, 424/135.1, 424/136.1, 424/141.1, 424/148.1,
424/149.1, 424/150.1, 424/159.1, 424/160.1, 424/161.1, 424/164.1, 424/165.1, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 4. Document ID: US 20020010318 A1

L1: Entry 4 of 12

File: PGPB

Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020010318

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020010318 A1

TITLE: Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Niven, Ralph W.	Redwood City	CA	US	
Wright, Clifford D.	Boulder	CO	US	
Chang, Byeong S.	Thousand Oaks	CA	US	

US-CL-CURRENT: 530/350; 435/183

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 20010006939 A1

L1: Entry 5 of 12

File: PGPB

Jul 5, 2001

PGPUB-DOCUMENT-NUMBER: 20010006939

PGPUB-FILING-TYPE: new-utility

DOCUMENT-IDENTIFIER: US 20010006939 A1

TITLE: SECRETORY LEUKOCYTE PROTEASE INHIBITOR DRY POWDER PHARMACEUTICAL COMPOSITIONS

PUBLICATION-DATE: July 5, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
NIVEN, RALPH W.	REDWOOD CITY	CA	US	
WRIGHT, CLIFFORD D.	BOULDER	CO	US	
CHANG, BYEONG S.	THOUSAND OAKS	CA	US	

US-CL-CURRENT: 514/2; 435/69.1, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 6. Document ID: US 6436403 B1

L1: Entry 6 of 12

File: USPT

Aug 20, 2002

US-PAT-NO: 6436403

DOCUMENT-IDENTIFIER: US 6436403 B1

TITLE: Pharmaceutical composition of the intercellular adhesion molecule ICAM-1 for use in anti-viral prophylactic therapy

DATE-ISSUED: August 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Springer; Timothy A.	Newton	MA		
Staunton; Donald E.	Chestnut Hill	MA		

US-CL-CURRENT: 424/193.1; 424/184.1, 424/204.1, 435/235.1, 530/350, 530/403

ABSTRACT:

The invention concerns the use of functional derivatives of ICAM-1 to treat viral infection. The invention also provides a vaccine to prevent such infection, and a diagnostic assay to determine the existence and extent of such infection.

2 Claims, 18 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 7. Document ID: US 6365156 B1

L1: Entry 7 of 12

File: USPT

Apr 2, 2002

US-PAT-NO: 6365156

DOCUMENT-IDENTIFIER: US 6365156 B1

TITLE: Method for improving the half-life of soluble viral-specific ligands on mucosal membranes

DATE-ISSUED: April 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Peter P.	Palo Alto	CA		

US-CL-CURRENT: 424/147.1; 424/159.1, 424/163.1, 424/164.1, 424/196.11

ABSTRACT:

This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.

19 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: US 5693608 A

L1: Entry 8 of 12

File: USPT

Dec 2, 1997

US-PAT-NO: 5693608

DOCUMENT-IDENTIFIER: US 5693608 A

TITLE: Method of administering a biologically active substance

DATE-ISSUED: December 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bechgaard; Erik	Hellerup			DK
Gizurarson; Sveinbjorn	Keflavik			IS
Hjortkj.ae buttet.r; Rolf Kuhlman	Humleb.ae buttet.r			DK

US-CL-CURRENT: 514/2; 514/4, 530/300

ABSTRACT:

A method for administering a therapeutically effective amount of a biologically active substance to the circulatory system of a mammal including administering a pharmaceutical composition having a total volume of 1-1000 .mu.l to a nasal mucosal membrane of the mammal, the pharmaceutical composition including the therapeutically effective amount of the biologically active substance dissolved or suspended in a volume of 1-1000 .mu.l of an n-ethylene glycol containing vehicle including at least one n-ethylene glycol represented by the formula:

$$H(OCH.sub.2\ CH.sub.2).sub.p\ OH$$

wherein p is from 1 to 8, so that upon administration of the pharmaceutical composition to the nasal mucosal membrane, absorption of the biologically active substance through the mucosal membrane and into the blood stream of the mammal rapidly takes place and thereby allows the biologically active substance to exert its therapeutic effect.

30 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RMIC	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: US 5534496 A

L1: Entry 9 of 12

File: USPT

Jul 9, 1996

US-PAT-NO: 5534496

DOCUMENT-IDENTIFIER: US 5534496 A

TITLE: Methods and compositions to enhance epithelial drug transport

DATE-ISSUED: July 9, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Vincent H.	Monterey Park	CA		
Yen; Wan-Ching	Columbus	OH		

US-CL-CURRENT: 514/17; 424/434, 514/18, 514/19, 530/330, 530/331

ABSTRACT:

Methods and compositions provided for enhancing the transport of drugs (including peptides,

oligonucleotides, proteins and conventional drugs) across epithelial cells at mucosal sites. The methods and compositions include the use of a peptide comprising at least two amino acids, such as Pro-Leu-Gly-Pro-Arg or Pro-Leu, and a protective group such as phenylazo-benzyloxycarbonyl, N-methyl, t-butyloxycarbonyl, fluoroenylmethyloxycarbonyl or carbobenzoxy, at the N-terminus, or in a mixture of such peptides in a sufficient amount to enhance the drug transport across epithelial cells at mucosal sites. Preferably, the peptide comprises 2 to 5 amino acids; the N-terminal amino acids are preferably Pro-Leu. The peptide with the drug are introduced to the mucosal site in a physical mixture, a conjugated form or by a microcapsule, microsphere, liposome, cell, bacteria, virus or food vesicle carrier by an oral, nasal, pulmonary, buccal, rectal, transdermal, vaginal or ocular route.

8 Claims, 37 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 10. Document ID: US 5428006 A

L1: Entry 10 of 12

File: USPT

Jun 27, 1995

US-PAT-NO: 5428006

DOCUMENT-IDENTIFIER: US 5428006 A

TITLE: Method of administering a biologically active substance

DATE-ISSUED: June 27, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bechgaard; Erik	Hellerup			DK
Gizurarson; Sveinbjorn	Keflavik			IS
Hjortkjaer; Rolf K.	Humblebaer			DK

US-CL-CURRENT: 514/3; 514/2; 514/4; 530/303; 530/307; 530/311; 530/313

ABSTRACT:

A method for administering a therapeutically effective amount of a biologically active substance to the circulatory system of a mammal including administering a pharmaceutical composition having a total volume of 1-1000 .mu.l to a nasal mucosal membrane of the mammal, the pharmaceutical composition including the therapeutically effective amount of the biologically active substance dissolved or suspended in a volume of 1-1000 .mu.l of a n-glycofurol-containing vehicle including at least one n-glycofurol represented by the formula: ##STR1## wherein n is from 1 to 8, so that upon administration of the pharmaceutical composition to the nasal mucosal membrane, absorption of the biologically active substance through the mucosal membrane and into the blood stream of the mammal rapidly takes place and thereby allows the biologically active substance to exert its therapeutic effect.

22 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 11. Document ID: US 5397771 A

L1: Entry 11 of 12

File: USPT

Mar 14, 1995

US-PAT-NO: 5397771

DOCUMENT-IDENTIFIER: US 5397771 A

TITLE: Pharmaceutical preparation

DATE-ISSUED: March 14, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bechgaard; Erik	Hellerup			DK
Gizurarson; Sveinbjorn	Keflavik			IS
Hjortkjaer; Rolf K.	Humblebaer			DK

US-CL-CURRENT: 514/2; 514/3, 514/4, 530/303, 530/307, 530/311, 530/313

ABSTRACT:

A pharmaceutical preparation for application of an effective amount of one or more biologically active substance(s) to a mucosal membrane of a mammal comprising an n-glycofurool represented by the formula I: ##STR1## wherein n is 1 to 4 in an amount from: 0.1-30% preferably 0.1-20% most preferably 1-15% in water, or in vegetable oil or n-ethylene glycol(s) represented by formula II:

H(OCH.sub.2 CH.sub.2).sub.p OH

wherein p is 2 to 8, or in a mixture thereof. Nasal administration of the preparation produces a high plasma concentration of the pharmaceutically active substance(s) nearly as rapid as by i.v. administration.

29 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWC	Draw Desc	Image
-----	-----------	-------

☐ 12. Document ID: JP 2002532558 W WO 200037099 A2 AU 200019878 A EP 1140150 A2 CN 1334743 A

L1: Entry 12 of 12

File: DWPI

Oct 2, 2002

DERWENT-ACC-NO: 2000-452127

DERWENT-WEEK: 200279

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Stimulating mucociliary clearance rate of mucus and sputum in lung airways for treating lung diseases such as cystic fibrosis and bronchitis involves administering a Kunitz-type serine protease inhibitor

INVENTOR: HALL, R; NEWTON, B B ; POLL, C T ; TAYLOR, W J A

PRIORITY-DATA: 1999US-0441966 (November 17, 1999), 1998US-0218913 (December 22, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2002532558 W	October 2, 2002		227	A61K038/55
WO 200037099 A2	June 29, 2000	E	173	A61K038/57
AU 200019878 A	July 12, 2000		000	A61K038/57
EP 1140150 A2	October 10, 2001	E	000	A61K038/57
CN 1334743 A	February 6, 2002		000	A61K038/57

INT-CL (IPC): A61 K 9/12; A61 K 9/72; A61 K 38/55; A61 K 38/57; A61 K 47/02; A61 P 11/00; A61 P 11/02; A61 P 11/06; A61 P 11/12; A61 P 27/16; A61 P 43/00; C07 K 14/81

ABSTRACTED-PUB-NO: WO 200037099A

BASIC-ABSTRACT:

NOVELTY - Accelerating the rate of mucociliary clearance in a subject comprising administering

a composition (I) comprising a Kunitz-type serine protease inhibitor (KSPI).

ACTIVITY - Antiinflammatory. The effect of the Kunitz family serine protease inhibitor, bikunin, was studied on sheep tracheal mucus velocity (TMV) over 8 hours after treatment with bikunin. 9 mg bikunin (3 ml of 3 mg/ml) was administrated by a nebulized aerosol to the airways and to measure TMV, 5-10 radiopaque Teflon (RTM) particles were insufflated into the trachea via a catheter placed within the endotracheal tube. The movement of the Teflon (RTM) particles was then measured for 1 minute. TMV was calculated from the average distance in a cephalad direction traveled per minute for 5 - 10 Teflon particles. Baseline TMV was measured immediately prior to administration of the aerosol for 8 hours with an interval of 1 hour. The results showed that bikunin aerosol delivered to sheep airways significantly increased TMV at 8 hours compared to the same time for a group of animals receiving phosphate buffered saline (PBS) vehicle aerosol.

MECHANISM OF ACTION - Serine protease inhibitor.

USE - Kunitz-type serine protease inhibitors are useful for stimulating the rate of mucociliary clearance of mucus and sputum in the lung airways (claimed). The inhibitors are useful for treating lung diseases such as cystic fibrosis, chronic bronchitis, bronchiectasis and chronic sinusitis and glue ear caused by retention and accumulation of mucus.

ADVANTAGE - The composition reduces or eliminates mucus and sputum in lung airways in patients with chronic obstructive lung disease and reduces the risk of secondary lung infections and other adverse side effects, as well as avoiding or delaying the need for lung transplant surgery in cystic fibrosis patients. Inhibitors are human proteins and therefore reduce the risk of kidney damage on administration of large doses of Trasylol proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

[Generate Collection](#)[Print](#)

Terms	Documents
mucociliary clearance and (kunitz or bikunin or aprotinin)	12

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 20 of 30 returned.☐ 1. Document ID: US 20030096247 A1

L4: Entry 1 of 30

File: PGPB

May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096247

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030096247 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2, 800/8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 2. Document ID: US 20030092011 A1

L4: Entry 2 of 30

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092011

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030092011 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.9, 536/23.2, 800/3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 3. Document ID: US 20030027248 A1

L4: Entry 3 of 30

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027248

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030027248 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 435/6, 530/350, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 4. Document ID: US 20030027161 A1

L4: Entry 4 of 30

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027161

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030027161 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2, 800/8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 6384208 B1

L4: Entry 5 of 30

File: USPT

May 7, 2002

US-PAT-NO: 6384208

DOCUMENT-IDENTIFIER: US 6384208 B1

TITLE: Sequence directed DNA binding molecules compositions and methods

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andr�ws; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 536/24.1; 536/23.1

ABSTRACT:

The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test

sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

1 Claims, 71 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 6. Document ID: US 6313096 B1

L4: Entry 6 of 30

File: USPT

Nov 6, 2001

US-PAT-NO: 6313096
DOCUMENT-IDENTIFIER: US 6313096 B1

TITLE: Inhibitors of trypsin-like enzymes

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Claeson; Goran	London			GB
Philipp; Manfred Hans Wilhelm	Scarsdale	NY		

US-CL-CURRENT: 514/18; 514/15, 514/16, 514/17, 514/19, 530/330, 530/331

ABSTRACT:

Pharmaceutical compositions comprising compounds of the formula: ##STR1##

in which X=H or is an N-protecting group; Y is 1-10 a-amino acids; Q1 and Q2 taken together represent the residue of a diol; R is C.sub.1-4 alkyl; and the asymmetric carbon atom marked * may have the D- or L-configuration, are useful in therapeutic methods of inhibiting thrombin.

41 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 7. Document ID: US 6294648 B1

L4: Entry 7 of 30

File: USPT

Sep 25, 2001

US-PAT-NO: 6294648
DOCUMENT-IDENTIFIER: US 6294648 B1

TITLE: Protein having proteinase inhibitor activity

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Delaria; Kathy	Walnut Creek	CA		
Roczniak; Steve	Lafayette	CA		
Davies; Christopher	Walnut Creek	CA		

US-CL-CURRENT: 530/300

ABSTRACT:

BTL.009 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase, and chymotrypsin than towards trypsin-like proteinases. BTL.009, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: US 6180607 B1

L4: Entry 8 of 30

File: USPT

Jan 30, 2001

US-PAT-NO: 6180607
DOCUMENT-IDENTIFIER: US 6180607 B1

TITLE: Protein having proteinase inhibitor activity

DATE-ISSUED: January 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davies; Christopher	Walnut Creek	CA	94598	
Chen; Dadong	Alameda	CA	94501	
Roczniak; Steve	Lafayette	CA	94549	

US-CL-CURRENT: 514/12; 530/324

ABSTRACT:

BTL.010 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase-, and proteinase 3, than towards trypsin-like proteinases. BTL.010, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1,11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: US 6114308 A

L4: Entry 9 of 30

File: USPT

Sep 5, 2000

US-PAT-NO: 6114308

DOCUMENT-IDENTIFIER: US 6114308 A

TITLE: Inhibitors of trypsin-like enzymes

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Claeson; Goran	London			GB
Phillip; Manfred Hans Wilhelm	Scarsdale	NY		

US-CL-CURRENT: 514/18; 514/15, 514/16, 514/17, 514/19, 530/330, 530/331

ABSTRACT:

Pharmaceutical compositions comprising compounds of the formula: ##STR1## in which X.dbd.H or is an N-protecting group; Y is 1-10 .alpha.-amino acids; Q1 and Q2 taken together represent the residue of a diol; R is C.sub.1-4, alkyl; and the asymmetric carbon atom marked * may have the D- or L-configuration, are useful in therapeutic methods of inhibiting thrombin.

36 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 10. Document ID: US 6048717 A

L4: Entry 10 of 30

File: USPT

Apr 11, 2000

US-PAT-NO: 6048717

DOCUMENT-IDENTIFIER: US 6048717 A

TITLE: Inhibitors of catalytic antibodies

DATE-ISSUED: April 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Paul; Sudhir	Omaha	NE		
Powell; Michael J.	Gaithersburg	MD		
Massey; Richard J.	Rockville	MD		

US-CL-CURRENT: 435/188.5; 514/14, 530/327

ABSTRACT:

Specific, selective inhibitors of catalytic antibodies both synthetic and naturally occurring, their use and compositions thereof are disclosed. In particular, an inhibitor preventing the hydrolysis of the peptide bond between amino acid residues 16 and 17 in the neurotransmitter vasoactive intestinal peptide (VIP) by an anti-VIP catalytic autoantibody is disclosed.

14 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 11. Document ID: US 6010849 A

L4: Entry 11 of 30

File: USPT

Jan 4, 2000

US-PAT-NO: 6010849

DOCUMENT-IDENTIFIER: US 6010849 A

TITLE: Sequence-directed DNA binding molecules compositions and methods

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 435/6; 435/7.1

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

11 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-----------	-------

☐ 12. Document ID: US 5869241 A

L4: Entry 12 of 30

File: USPT

Feb 9, 1999

US-PAT-NO: 5869241

DOCUMENT-IDENTIFIER: US 5869241 A

TITLE: Method of determining DNA sequence preference of a DNA-binding molecule

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is

versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

11 Claims, 72 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 13. Document ID: US 5856306 A

L4: Entry 13 of 30

File: USPT

Jan 5, 1999

US-PAT-NO: 5856306

DOCUMENT-IDENTIFIER: US 5856306 A

**** See image for Certificate of Correction ****

TITLE: Inhibitors of trypsin-like enzymes

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Claeson; Goran	London			GB2
Philipp; Manfred Hans Wilhelm	Scarsdale	NY		
Metternich; Rainer	Inzlingen			DE

US-CL-CURRENT: 514/18; 514/15, 514/16, 514/17, 514/19

ABSTRACT:

Pharmaceutical compositions comprising compounds of the formula: ##STR1## in which X.dbd.H or is an N-protecting group; Y is 1-10 .alpha.-amino acids; Q1 and Q2 taken together represent the residue or a diol; R is C.sub.1-4 alkyl; and the asymmetric carbon atom marked * may have the D- or L-configuration, are useful in therapeutic methods of inhibiting thrombin.

12 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 14. Document ID: US 5744131 A

L4: Entry 14 of 30

File: USPT

Apr 28, 1998

US-PAT-NO: 5744131

DOCUMENT-IDENTIFIER: US 5744131 A

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: April 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		

US-CL-CURRENT: 424/78.08; 436/501, 514/1

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

3 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

 15. Document ID: US 5738990 A

L4: Entry 15 of 30

File: USPT

Apr 14, 1998

US-PAT-NO: 5738990

DOCUMENT-IDENTIFIER: US 5738990 A

** See image for Certificate of Correction **

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: April 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/24.1

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

5 Claims, 48 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 16. Document ID: US 5726014 A

L4: Entry 16 of 30

File: USPT

Mar 10, 1998

US-PAT-NO: 5726014
DOCUMENT-IDENTIFIER: US 5726014 A

TITLE: Screening assay for the detection of DNA-binding molecules

DATE-ISSUED: March 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Watertown	MA		
Turin; Lisa M.	Berkeley	CA		

US-CL-CURRENT: 435/6; 435/91.2, 436/501

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

19 Claims, 72 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 17. Document ID: US 5716780 A

L4: Entry 17 of 30

File: USPT

Feb 10, 1998

US-PAT-NO: 5716780
DOCUMENT-IDENTIFIER: US 5716780 A

TITLE: Method of constructing sequence-specific DNA-binding molecules

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Watertown	MA		

US-CL-CURRENT: 435/6; 436/501

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

9 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KINC	Draw Desc	Image
------	-----------	-------

☐ 18. Document ID: US 5693463 A

L4: Entry 18 of 30

File: USPT

Dec 2, 1997

US-PAT-NO: 5693463
DOCUMENT-IDENTIFIER: US 5693463 A

TITLE: Method of ordering sequence binding preferences of a DNA-binding molecule

DATE-ISSUED: December 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		

US-CL-CURRENT: 435/6; 435/7.23, 536/23.1

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

3 Claims, 48 Drawing figures
Exemplary Claim Number: 1

Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 19. Document ID: US 5602015 A

L4: Entry 19 of 30

File: USPT

Feb 11, 1997

US-PAT-NO: 5602015

DOCUMENT-IDENTIFIER: US 5602015 A

TITLE: Autoantibodies which enhance the rate of a chemical reaction

DATE-ISSUED: February 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sudhir; Paul	Omaha	NE		

US-CL-CURRENT: 435/188.5; 435/219, 435/226

ABSTRACT:

Autoantibodies which enhance the rate of a chemical reaction of a substrate, processes for their preparation, their use and compositions thereof are disclosed. In particular, an autoantibody capable of catalyzing the hydrolysis of the peptide bond between amino acid residues Thr.sup.7 -Asp.sup.8, Arg.sup.14 -Lys.sup.15, Gln.sup.16 -Met.sup.17, Met.sup.17 -Ala.sup.18, Ala.sup.18 -Val.sup.19, Lys.sub.20 -Lys.sup.21, Lys.sup.21 -Tyr.sup.22 in the neurotransmitter vasoactive intestinal peptide (VIP) is disclosed.

46 Claims, 24 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 20. Document ID: US 5599538 A

L4: Entry 20 of 30

File: USPT

Feb 4, 1997

US-PAT-NO: 5599538

DOCUMENT-IDENTIFIER: US 5599538 A

TITLE: Autoantibodies which enhance the rate of a chemical reaction

DATE-ISSUED: February 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Paul; Sudhir	Omaha	NE		
Li; Lan	Omaha	NE		
Kaveri; Srini	Villejuif			FR

US-CL-CURRENT: 424/130.1; 424/143.1, 424/175.1, 424/94.1, 435/188.5

ABSTRACT:

Autoantibodies which enhance the rate of a chemical reaction of a substrate, processes for their preparation, their use and compositions thereof are disclosed. In particular, an autoantibody capable of catalyzing the hydrolysis of the peptide bond between amino acid

residues 16 and 17 in the neurotransmitter vasoactive intestinal peptide (VIP) is disclosed. Human anti-thyroglobulin antibodies isolated by chromatography on protein-A and immobilized Tg hydrolyzed radiolabeled Tg, as shown by generation of several lower-sized products on SDS-electrophoresis gels. The activity displayed a $K_{sub.m}$ value of a 39 nM property typical of an antibody-combining site. Tg-antibodies also hydrolyzed commercially available peptidyl-methylcoumarinamide (MCA) substrates, displaying a preference for arg-MCA and lys-MCA containing conjugates. The hydrolysis of pro-phe-arg-MCA was characterized by $K_{sub.m}$ (17 μ M) and $k_{sub.cat}$ 0.06 min.^{sup.}-1. Peptidyl-MCA hydrolysis was inhibited potently by thyroglobulin ($K_{sub.i}$ 24 nM), suggesting a catalytic site/located in the antibody combining site. In control experiments, the hydrolytic activities were removed by immunoadsorption with immobilized anti-human IgG, and IgG depleted of the Tg-specific antibodies by affinity chromatography did not display Tg and pro-phe-arg-MCA hydrolyzing activities.

8 Claims, 27 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

[Generate Collection](#)[Print](#)

Terms	Documents
(bronchitis or bronchie\$7 or asthma or cystic fibrosis) same (kunitz or bikunin or aprotinin)	30

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 30 of 30 returned.**☐ **21. Document ID: US 5578444 A**

L4: Entry 21 of 30

File: USPT

Nov 26, 1996

US-PAT-NO: 5578444

DOCUMENT-IDENTIFIER: US 5578444 A

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: November 26, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 435/6; 435/7.23, 536/23.1

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

15 Claims, 71 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ **22. Document ID: US 5574014 A**

L4: Entry 22 of 30

File: USPT

Nov 12, 1996

US-PAT-NO: 5574014

DOCUMENT-IDENTIFIER: US 5574014 A

**** See image for Certificate of Correction ****

TITLE: Inhibitors of trypsin-like enzymes

DATE-ISSUED: November 12, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Claeson; Goran	London			GB2
Philipp; Manfred H. W.	Scarsdale	NY		
Metternich; Rainer	Inzlingen			DE

US-CL-CURRENT: 514/18; 514/19, 530/330, 530/331

ABSTRACT:

Pharmaceutical compositions comprising compounds of the formula: ##STR1## in which X=H or is an N-protecting group; Y is Phe-Pro; Q1 and Q2 taken together represent the residue of a diol; R is C.sub.1-4 alkyl; and the asymmetric carbon atom marked * may have the D- or L-configuration, are useful in therapeutic methods of inhibiting thrombin.

14 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-----------	-------

☐ 23. Document ID: US 5288707 A

L4: Entry 23 of 30

File: USPT

Feb 22, 1994

US-PAT-NO: 5288707
DOCUMENT-IDENTIFIER: US 5288707 A

TITLE: Borolysine peptidomimetics

DATE-ISSUED: February 22, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Metternich; Rainer	Inzlingen			DE

US-CL-CURRENT: 514/19; 514/18, 514/64, 530/330, 530/331, 548/110

ABSTRACT:

Borolysine peptidomimetics of formula I ##STR1## wherein W, Y, R.sub.4, R.sub.5, Q.sub.1 and Q.sub.2 are defined in claim 1 are potent thrombin inhibitors.

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-----------	-------

☐ 24. Document ID: US 5236836 A

L4: Entry 24 of 30

File: USPT

Aug 17, 1993

US-PAT-NO: 5236836
DOCUMENT-IDENTIFIER: US 5236836 A
** See image for Certificate of Correction **

TITLE: Autoantibodies which enhance the rate of a chemical reaction

DATE-ISSUED: August 17, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Paul; Sudhir	Omaha	NE		

US-CL-CURRENT: 435/188.5; 435/226, 435/68.1, 530/388.24, 530/389.2

ABSTRACT:

Autoantibodies which enhance the rate of a chemical reaction of a substrate, processes for their preparation, their use and compositions thereof are disclosed. In particular, an autoantibody capable of catalyzing the hydrolysis of the peptide bond between amino acid residues 16 and 17 in the neurotransmitter vasoactive intestinal peptide (VIP) is disclosed.

13 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 25. Document ID: US 5194585 A

L4: Entry 25 of 30

File: USPT

Mar 16, 1993

US-PAT-NO: 5194585
DOCUMENT-IDENTIFIER: US 5194585 A

TITLE: Inhibitors of catalytic antibodies

DATE-ISSUED: March 16, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Paul; Sudhir	Omaha	NE		
Powell; Michael J.	Gaithersburg	MD		
Massey; Richard J.	Rockville	MD		

US-CL-CURRENT: 530/309; 424/810, 435/188.5, 514/14, 514/16, 530/327, 530/328, 530/329, 530/868

ABSTRACT:

Specific, selective inhibitors of catalytic antibodies both synthetic and naturally occurring, their use and compositions thereof are disclosed. In particular, an inhibitor preventing the hydrolysis of the peptide bond between amino acid residues 16 and 17 in the neurotransmitter vasoactive intestinal peptide (VIP) by an anti-VIP catalytic autoantibody is disclosed.

10 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 26. Document ID: US 6180607 B1

L4: Entry 26 of 30

File: DWPI

Jan 30, 2001

DERWENT-ACC-NO: 2001-190860
DERWENT-WEEK: 200119
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Novel serine proteinase inhibitor of the Kunitz family, BTL.010 useful for treating emphysema, cystic fibrosis, adult respiratory distress syndrome, rheumatoid arthritis, organ failure and glomerulonephritis

INVENTOR: CHEN, D; DAVIES, C ; ROCZNIAK, S

PRIORITY-DATA: 1999US-0369494 (August 5, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6180607 B1	January 30, 2001		017	A61K038/00

INT-CL (IPC): A61 K 38/00; C07 K 5/00

ABSTRACTED-PUB-NO: US 6180607B

BASIC-ABSTRACT:

NOVELTY - A serine proteinase inhibitor of the Kunitz family (BTL.010) (I) comprising an amino acid sequence which is at least 60% identical over 50 residues to a sequence (S) comprising 58 amino acids fully defined in the specification, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a pharmaceutical composition (II), comprising (I), for inhibiting protease activity.

ACTIVITY - Nephrotropic; antirheumatic; antiarthritic.

MECHANISM OF ACTION - Inhibitor of protease (claimed). No supporting data is given.

USE - (I) is useful for inhibiting protease activity by contacting the protease with (I), within a human patient. (I) is useful for treating, or ameliorating a medical condition such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure or glomerulonephritis, in an individual, which condition, if left untreated, results in tissue damage caused by proteolysis by a serine protease, by administering (II) prior to tissue damage, to the individual. (II) modulates at least one physiological condition such as platelet activation, blood coagulation, neutrophil activation, or monocyte activation (claimed). (I) is useful for the prophylactic or therapeutic treatment of patient undergoing angioplasty and for the treatment of inflammatory diseases and diseases involving lung and vascular injury.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-----	-----------	-------

☐ 27. Document ID: JP 2002532558 W WO 200037099 A2 AU 200019878 A EP 1140150 A2 CN 1334743 A

L4: Entry 27 of 30

File:.DWPI

Oct 2, 2002

DERWENT-ACC-NO: 2000-452127

DERWENT-WEEK: 200279

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Stimulating mucociliary clearance rate of mucus and sputum in lung airways for treating lung diseases such as cystic fibrosis and bronchitis involves administering a Kunitz-type serine protease inhibitor

INVENTOR: HALL, R; NEWTON, B B ; POLL, C T ; TAYLOR, W J A

PRIORITY-DATA: 1999US-0441966 (November 17, 1999), 1998US-0218913 (December 22, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2002532558 W	October 2, 2002		227	A61K038/55
WO 200037099 A2	June 29, 2000	E	173	A61K038/57
AU 200019878 A	July 12, 2000		000	A61K038/57
EP 1140150 A2	October 10, 2001	E	000	A61K038/57
CN 1334743 A	February 6, 2002		000	A61K038/57

INT-CL (IPC): A61 K 9/12; A61 K 9/72; A61 K 38/55; A61 K 38/57; A61 K 47/02; A61 P 11/00; A61 P 11/02; A61 P 11/06; A61 P 11/12; A61 P 27/16; A61 P 43/00; C07 K 14/81

ABSTRACTED-PUB-NO: WO 200037099A
BASIC-ABSTRACT:

NOVELTY - Accelerating the rate of mucociliary clearance in a subject comprising administering a composition (I) comprising a Kunitz-type serine protease inhibitor (KSPI).

ACTIVITY - Antiinflammatory. The effect of the Kunitz family serine protease inhibitor, bikunin, was studied on sheep tracheal mucus velocity (TMV) over 8 hours after treatment with bikunin. 9 mg bikunin (3 ml of 3 mg/ml) was administered by a nebulized aerosol to the airways and to measure TMV, 5-10 radiopaque Teflon (RTM) particles were insufflated into the trachea via a catheter placed within the endotracheal tube. The movement of the Teflon (RTM) particles was then measured for 1 minute. TMV was calculated from the average distance in a cephalad direction traveled per minute for 5 - 10 Teflon particles. Baseline TMV was measured immediately prior to administration of the aerosol for 8 hours with an interval of 1 hour. The results showed that bikunin aerosol delivered to sheep airways significantly increased TMV at 8 hours compared to the same time for a group of animals receiving phosphate buffered saline (PBS) vehicle aerosol.

MECHANISM OF ACTION - Serine protease inhibitor.

USE - Kunitz-type serine protease inhibitors are useful for stimulating the rate of mucociliary clearance of mucus and sputum in the lung airways (claimed). The inhibitors are useful for treating lung diseases such as cystic fibrosis, chronic bronchitis, bronchiectasis and chronic sinusitis and glue ear caused by retention and accumulation of mucus.

ADVANTAGE - The composition reduces or eliminates mucus and sputum in lung airways in patients with chronic obstructive lung disease and reduces the risk of secondary lung infections and other adverse side effects, as well as avoiding or delaying the need for lung transplant surgery in cystic fibrosis patients. Inhibitors are human proteins and therefore reduce the risk of kidney damage on administration of large doses of Trasylol proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-----------	-------

28. Document ID: WO 9620278 A2 JP 10510996 W US 5663143 A EP 797666 A1

L4: Entry 28 of 30

File: DWPI

Jul 4, 1996

DERWENT-ACC-NO: 1996-321851
DERWENT-WEEK: 199902
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New engineered inhibitors of human neutrophil elastase - contg. aprotinin-like Kunitz domain for treating, e.g. cystic fibrosis or other respiratory disorders

INVENTOR: GUTERMAN, S; KENT, R ; LADNER, R C ; LEY, A C ; MARKLAND, W ; ROBERTS, B ; GUTERMAN, S K ; KENT, R B ; ROBERTS, B L

PRIORITY-DATA: 1994US-0358160 (December 16, 1994), 1988US-0240160 (September 2, 1988), 1990US-0487063 (March 2, 1990), 1991US-0664989 (March 1, 1991), 1993US-0009319 (January 26, 1993), 1993US-0133031 (October 13, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9620278 A2	July 4, 1996	E	106	C12N015/15
JP 10510996 W	October 27, 1998		116	C12N015/09
US 5663143 A	September 2, 1997		147	A61K037/00
EP 797666 A1	October 1, 1997	E	000	C12N015/15

INT-CL (IPC): A61 K 37/00; A61 K 38/55; A61 K 38/57; C07 K 14/81; C12 N 1/15; C12 N 1/19; C12 N 15/09; C12 N 15/15; C12 P 21/02

ABSTRACTED-PUB-NO: US 5663143A
BASIC-ABSTRACT:

Non-natural protein (I) comprises an engineered aprotinin-like Kunitz domain and inhibits human neutrophil elastase (hNE) with $K_i < 50$ pM. The domain has an amino acid (aa) sequence at least substantially homologous, over a region extending from first to last Cys, with one of the

reference sequences EPI-HNE-3 or -4; DPI.1.1, 1.2, 1.3, 2.1, 2.2, 2.3, 3.1, 3.2, 3.3, 4.1, 4.2, 4.3, 5.1, 5.2, 5.3, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 7.1, 7.2, 7.3, 7.4, 7.5, 8.1, 8.2, 8.3, 9.1, 9.2 or 9.3, but is not identical to any domain selected from EpiNE- alpha , EpiNE1-8, ITI-E7, BITI-E7-1222 , BITI-E7-141, AMINO 1 or 2, MUTP1, MUTT26A, MUTQE or MUT1619. Also new are (1) DNA (II) encoding (I); (2) expression vectors contg. (I) operably linked to regulatory sequences; (3) transformed cells contg. such vectors. The specification includes the sequences of the reference domains.

USE - (I) are inhibitors of hNE so are used to treat hereditary deficiency of circulating alpha -1-protease inhibitor (API), smoker's emphysema, destruction of lung tissue caused by excessive hNE activity, cystic fibrosis and other respiratory diseases.

ADVANTAGE - Unlike API, (I) are small, stable and non-toxic inhibitors of hNE.

ABSTRACTED-PUB-NO:

WO 9620278A EQUIVALENT-ABSTRACTS:

A protein that binds and inhibits human neutrophil elastase with a Ki less than about 10 picomolar comprising an amino acid sequence picked from the set of sequences EpiNE1, EpiNE2, EpiNE3, EpiNE4, EpiNE5, EpiNE6, EpiNE7, EpiNE8, EPI-HNE-2, EPI-HNE-3, EPI-HNE-4, BITI-E7, BITI-E7-141, BITI-E7-1222, MUT1619, MUTP1, AMINO1, AMINO2, MUTQE, MUTT26A, EpiNE7.6, EpiNE7.8, EpiNE7.9, EpiNE7.31, EpiNE 7.11, EpiNE7.7, EpiNE7.4, EpiNE7.14, EpiNE7.5, EpiNE7.10, EpiNE7.20, EpiNE7.1, EpiNE7.16, EpiNE7.19, EpiNE7.12, EpiNE7.17, EpiNE7.21, EpiNE7.22, EpiNE7.23, EpiNE7.24, EpiNE7.25, EpiNE7.26, EpiNE7.27, EpiNE7.28, EpiNE7.29, EpiNE7.30, EpiNE7.32, EpiNE7.33, EpiNE7.36, EpiNE7.37, EpiNE7.38, EpiNE7.39, and EpiNE7.40.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RWIC	Draw Desc	Image
------	-----------	-------



29. Document ID: JP 06192085 A

L4: Entry 29 of 30

File: DWPI

Jul 12, 1994

DERWENT-ACC-NO: 1994-260420

DERWENT-WEEK: 199432

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Drug for treating mite allergy e.g. asthma, allergic rhinitis and atopic dermatitis - contains aprotinin, potato protease inhibitor, soybean trypsin inhibitor, antipine, leupeptin, guanidine fatty acid derivs. guanidino-benzoic acid derivs. and/or amino-di:phenol(s)

PRIORITY-DATA: 1992JP-0253437 (August 31, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 06192085 A	July 12, 1994		012	A61K031/22

INT-CL (IPC): A61K 31/19; A61K 31/22; A61K 31/40; A61K 31/415; A61K 37/64

ABSTRACTED-PUB-NO: JP 06192085A

BASIC-ABSTRACT:

Drug for mite allergy contains aprotinin, potato protease inhibitor, soybean trypsin inhibitor, antipine, leupeptin, guanidine fatty acid derivs., guanidinobenzoic acid derivs. and/or aminodiphenols.

Pref. guanidine fatty acids are 6-guanidinohexanoic acid p-ethoxycarbonylphenylester and its acid addn. salts.; guanidinobenzoic acids are p-(p-guanidinobenzoyloxy)-phenylacetic acid N,N-dimethylcarbamoyl methylester, p-guanidinobenzoic acid 1-(N, N-dimethylcarbamoyl methoxy-carbonyl) -2-naphthylester, p-guanidinobenzoic acid p-(N-phenyl-N- ethoxycarbonylmethyl carbamoylmethyl) phenylester, etc.; amidinophenol derivs. are 5-(p-(p-amidino phenoxy carbonyl) -benzylidene) -3-ethoxycarbonyl methyl rhodanine, 1-(p-(p-amidinophenoxy carbonyl)benzyl) -2-isopropylimidazole etc.

USE/ADVANTAGE - The drug is used for prevention and treatment of mite allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Clip Img	Image								

KWIC	Drawn Desc
------	------------

☐ 30. Document ID: DE 3237253 A

L4: Entry 30 of 30

File: DWPI

Oct 6, 1983

DERWENT-ACC-NO: 1983-783934
DERWENT-WEEK: 198341
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Exercise- and analgesic-induced bronchial asthma treatment - with protease inhibitors
e.g. 4-amino:methyl-benzoic acid

INVENTOR: HUMMEL, S; SLAPKE, J ; WISCHNEWSK, G

PRIORITY-DATA: 1981DD-0236177 (December 23, 1981)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 3237253 A	October 6, 1983		009	

INT-CL (IPC): A61K 31/19; A61K 37/64; A61K 45/06

ABSTRACTED-PUB-NO: DE 3237253A
BASIC-ABSTRACT:

New agents for eliminating and preventing stress- and analgesic-induced bronchial asthma attacks contain protease inhibitors as active substances.

The agents are based on the hypothesis that stress-induced bronchial asthma is attributable to a deficiency of protease inhibitors, while analgesic-induced asthma is attributable to effects of analgesics on cyclooxygenase and GSH-independent peroxidase. Pref. protease inhibitors are p-aminomethylbenzoic acid, epsilon-amino-caproic acid, 4-aminomethylcyclohexane-L carboxylic acid, N-alpha-p-tosyl-L-lysine-chloromethyl ketone, N-acetyl-L-tyrosine ethyl ester, alpha 1-antitrypsin, p-tosyl-L-arginine methyl ester, aprotinin, leupeptin, antipain, 4-amidino-phenylpyruvic acid, azexomic acid, tranexamic acid or various subst. benzamidines.

Used for treatment and prophylaxis of bronchial asthma attacks induced by physical stress or by analgesics, antipyretics and non-steroidal anti-inflammatory agents.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Drawn Desc	Image
------	------------	-------

[Generate Collection](#)[Print](#)

Terms	Documents
(bronchitis or bronchie\$7 or asthma or cystic fibrosis) same (kunitz or bikunin or aprotinin)	30

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)